Format

Send to

Choose Destination
Eur Urol Focus. 2018 Oct 11. pii: S2405-4569(18)30294-3. doi: 10.1016/j.euf.2018.10.001. [Epub ahead of print]

Urine Gene Expression Profiles in Bladder Pain Syndrome Patients Treated with Triamcinolone.

Author information

1
Department and Laboratory of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
2
Female and Functional Urology Department, Fundació Puigvert, Barcelona, Spain.
3
Bioinformatics Platform, CIBEREHD, Barcelona, Spain.
4
Department and Laboratory of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. Electronic address: lmengual@clinic.cat.

Abstract

BACKGROUND:

The pathogenesis of bladder pain syndrome (BPS) remains incompletely defined, and there is no standard treatment for BPS as yet.

OBJECTIVE:

To gain detailed insight into the disease pathobiology of BPS through comparative gene expression analysis of urine from BPS patients versus control individuals and, furthermore, to determine the efficacy of triamcinolone treatment in BPS patients in terms of the gene expression profiles in urine.

DESIGN, SETTING, AND PARTICIPANTS:

A prospective pilot study including 21 urine samples from patients with Hunner's lesions (n=6) and controls (n=9) between January and August 2017.

INTERVENTION:

Triamcinolone treatment of BPS patients.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

Urine samples from BPS patients were collected before (pretreatment group) and 2 wk after triamcinolone treatment (post-treatment group). Gene expression of urine sediment was analyzed using RNA sequencing. Pathways and biological processes in which differentially expressed genes are involved were analyzed.

RESULTS AND LIMITATIONS:

A total of 3745 genes were found to be differentially expressed between the three groups tested. Gene expression differences between controls and BPS samples (630 differentially expressed genes) were more pronounced than the differences between pre- and post-treatment BPS samples (197 differentially expressed genes). Gen Set Enrichment Analysis showed that differentially expressed genes in BPS patients (pretreatment), compared with controls, were enriched for some functional gene networks associated with several metabolic processes and ribosome biogenesis. The limited number of patients included may not accurately represent the BPS population.

CONCLUSIONS:

Gene expression profiles of urine sediment are able to discriminate between BPS and control patients. Moreover, we show that triamcinolone induces changes in urine gene expression profiles.

PATIENT SUMMARY:

In this report, we looked at gene expression profiles of urine sediment from patients with Hunner's lesions, before and after triamcinolone treatment, and control individuals. We found that urine gene expression profiles are able to discriminate Hunner's lesions patients from controls. Furthermore, we report, for the first time, that triamcinolone treatment of patients with Hunner's lesions induces changes in bladder gene expression profiles that can be observed in urine samples.

KEYWORDS:

Gene expression; Painful bladder syndrome; RNA sequencing; Triamcinolone; Urine

PMID:
30318464
DOI:
10.1016/j.euf.2018.10.001

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center